

## 12. BÖLÜM

# Derin Ven Trombozunda Medikal Tedavi

Ahmet Burak TATLI<sup>1</sup>

### Giriş


Derin ven trombozu (DVT), genellikle alt ekstremitelerdeki derin yerleşimli venlerde tromboz oluşumu ile seyreden bir patolojidir. En ciddi komplikasyonu pulmoner embolidir (PE) ve pulmoner emboli ile birlikte venöz tromboemboli (VTE) adı verilen klinik tabloyu oluşturur. Derin ven trombozu tedavisindeki amaç; pulmoner emboli, kronik tromboembolik pulmoner hipertansiyon (KTEPH), posttrombotik sendrom, kronik periferik venöz hastalık gelişmesini ve VTE nüksünü önlemektir [1,2].

Son yıllarda yapılan araştırmalarda venöz tromboemboli insidansında artış olduğu gözlenmektedir. Yıllık ortalama insidansı 104-183/100000 kişi kadar olup yüksek riskli vakalarda bu oran 68/1000 'e kadar artmaktadır [3,4]. Nüfusun yaşam süresinin uzaması ve kanser vakalarındaki artış buna etken olarak gösterilmektedir.

### Derin Ven Trombozunun Tedavisi

Günümüzde mevcut tedavi seçenekleri arasında; antikoagülan tedavi, trombolitik tedavi ve cerrahi tedavi seçenekleri öne çıkmaktadır (Tablo 1) [5]. Antikoagülan tedavi, DVT 'nin medikal tedavisinin temelini oluşturmaktadır. Tanısı konmuş ya da klinik şüphesi yüksek ancak tanı testleri geciken tüm hastalara antikoagülan tedavi derhal başlanmalıdır (Kanıt düzeyi B) [5]. Buradaki amaç, mevcut trombüsün progresyonunu ve rekürren tromboz oluşumunu engellemek ve sonucunda PE insidansını düşürmektir.

<sup>1</sup> Kalp ve Damar Cerrahisi Uzmanı, Kırklareli Devlet Hastanesi, ahmetburaktatli@gmail.com



**Şekil 2:** Akut DVT tedavisinde algoritma şeması [16]

(DVT: Derin ven trombozu; PE: Pulmoner emboli; USG: Ultrason; VKA: Vitamin K antagonistleri; YOAK: Yeni nesil oral antikoagülanlar; DMAH: Düşük molekül ağırlıklı heparin)

## Kaynaklar

1. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest*. 2008 Jun;133(6 Suppl):454S-545S.
2. Zhu T, Martinez I, Emmerich I. Venous thromboembolism: risk factors for recurrence. *Arterioscler Vasc Biol* 2009;29:298-310.
3. Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. *J Thromb Thrombolysis* 2016;41:3-14.
4. Demir AM, Ümit EG. Kanserle ilişkili tromboz. *Türkiye Klinikleri J Hematol-Special Topics* 2015;8:66-74.
5. Demir M, Erdemli B, Kurtoğlu M, Öngen G. Ulusal Venöz Tromboembolizm Profilaksi ve Tedavi Kılavuzu. İstanbul: Cortex; 2010.
6. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012;141:419-94.
7. Türk Kalp Damar Cerrahisi Derneği. Periferik Arter ve Ven Hastalıkları Tedavi Kılavuzu - 2008. Öncü Basımevi. 2008, Ankara.
8. Bozkurt AK. Periferik arter ve ven hastalıkları ulusal tedavi kılavuzu 2016. İstanbul: Bayçınar Tıbbi Yayıncılık; 2016.
9. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. *Chest* 2016;149:315-52.
10. Lensing AWA, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low molecular weight heparins: a meta analysis. *Arch Intern Med* 1995;155: 601-607.
11. Ertaş F, Kaya H, Kaya Z, Bulur S, Köse N, Gül M, et al. Epidemiology of atrial fibrillation in Turkey: preliminary results of the multicenter AFTER study. *Türk Kardiyol Dern Ars* 2013;41:99-104.



31. Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, et al. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. *N Engl J Med* 2016;375:1131-41.
32. Kearon C, Ageno W, Cannegieter SC, Cosmi B, Geersing GJ, Kyrle PA. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. *J Thromb Haemost.* 2016 Jul;14(7):1480-3.
33. Stevens SM, Woller SC, Bauer KA, Kasthuri R, Cushman M, Streiff M et al. Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. *J Thromb Thrombolysis.* 2016 Jan;41(1):154-64.
34. Douketis J, Tosetto A, Marcucci M, Baglin T, Cosmi B, Cushman M, et al. Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. *BMJ* 2011;342:813.
35. Kearon C, Spencer FA, O'Keefe D, Parpia S, Schulman S, Baglin T, et al. D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. *Ann Intern Med* 2015;162:27-34.
36. Kruger PC, Eikelboom JW, Douketis JD, Hankey GJ. Deep vein thrombosis: update on diagnosis and management. *Med J Aust.* 2019 Jun;210(11):516-524.
37. Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. *N Engl J Med* 2013;368:709-18.
38. Romualdi E, Donadini MP, Ageno W. Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study). *Expert Rev Cardiovasc Ther* 2011;9:841-4.
39. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Apixaban for extended treatment of venous thromboembolism. *N Engl J Med* 2013;368:699-708.
40. Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H et al. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. *N Engl J Med.* 2017 Mar 30;376(13):1211-1222.
41. Kahn SR, Shapiro S, Wells PS, Rodger MA, Kovacs MJ, Anderson DR, et al. Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. *Lancet* 2014;383:880-8.
42. Ten Cate-Hoek AJ, Amin EE, Bouman AC, Meijer K, Tick LW, Middeldorp S et al. Individualised versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome (IDEAL DVT): a multicentre, randomised, single-blind, allocation-concealed, non-inferiority trial. *Lancet Haematol.* 2018 Jan;5(1):e25-e33.
43. Amin EE, Bistervels IM, Meijer K, Tick LW, Middeldorp S, Mostard G et al. Reduced incidence of vein occlusion and postthrombotic syndrome after immediate compression for deep vein thrombosis. *Blood.* 2018 Nov 22;132(21):2298-2304.
44. Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. *J Clin Oncol.* 2015 Feb 20;33(6):654-6.
45. Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D et al. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. *N Engl J Med.* 2018 Feb 15;378(7):615-624.
46. Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C et al. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients

- With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). *J Clin Oncol*. 2018 Jul 10;36(20):2017-2023.
47. Carrier M, Blais N, Crowther M, Kavan P, Le Gal G, Moodley O et al. Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus. *Curr Oncol*. 2018 Oct;25(5):329-337.
  48. Suryanarayan D, Lee AYY, Wu C. Direct Oral Anticoagulants in Cancer Patients. *Semin Thromb Hemost*. 2019 Sep;45(6):638-647.
  49. Mazzolai L, Aboyans V, Ageno W, Agnelli G, Alatri A, Bauersachs R et al. Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. *Eur Heart J*. 2018 Dec 14;39(47):4208-4218.
  50. Beyer-Westendorf J, Michalski F, Tittl L, Middeldorp S, Cohen H, Abdul Kadir R et al. Pregnancy outcome in patients exposed to direct oral anticoagulants - and the challenge of event reporting. *Thromb Haemost*. 2016 Sep 27;116(4):651-8.
  51. Palareti G. How I treat isolated distal deep vein thrombosis (IDDDVT). *Blood* 2014; 123: 1802–1809.
  52. Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. *N Engl J Med* 2018; 378: 2010–2021.
  53. Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffatti A et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. *Blood*. 2018 Sep 27;132(13):1365-1371.
  54. Porath AD, Clodfelter S, Slaton T, Bookhart BK, Kozma CM, Rand ML et al. Policy Change for Deep Vein Thrombosis: Effects on Length of Stay and Hospitalization Costs of Moving From Warfarin to Direct Oral Anticoagulants. *Clin Ther*. 2019 Feb;41(2):269-279.
  55. Heneghan CJ, Garcia-Alamino JM, Spencer EA, Ward AM, Perera R, Bankhead C et al. Self-monitoring and self-management of oral anticoagulation. *Cochrane Database Syst Rev*. 2016 Jul 5;7:CD003839.
  56. Witt DM, Nieuwlaat R, Clark NP, Ansell J, Holbrook A, Skov J et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. *Blood Adv*. 2018 Nov 27;2(22):3257-3291.
  57. Andreozzi GM, Bignamini AA, Davì G, Palareti G, Matuška J, Holý M et al. Sulodexide for the Prevention of Recurrent Venous Thromboembolism: The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. *Circulation*. 2015 Nov 17;132(20):1891-7.
  58. Schmidt M, Cannegieter SC, Johannesdottir SA, Dekkers OM, Horváth-Puhó E, Sørensen HT. Statin use and venous thromboembolism recurrence: a combined nationwide cohort and nested case-control study. *J Thromb Haemost* 2014; 12: 1207–15.
  59. Jiang QJ, Bai J, Jin J, Shi J, Qu L. Sulodexide for Secondary Prevention of Recurrent Venous Thromboembolism: A Systematic Review and Meta-Analysis. *Front Pharmacol*. 2018 Aug 8;9:876.